By exerting these functions, it can interact at multiple stages of the cancer-immunity cycle [47]: (i) release antigens via (immunogenic) cytotoxicity, (ii) instigate antigen presentation by DC, (iii) aid T-cell priming by releasing IFN-α/β and other cytokines, (iv) stimulate T-cell recruitment via tumor- and macrophage-secreted chemokines, and (v) improve T-cell recognition of tumor cells via increased MHC expression. This evidence concerns the gene IFNA1 and cancer.